MBX MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 98% planned / 2% discretionary
Largest single sale: $2.1M.
Where they traded
Last open-market purchase: March 13, 2026 , by Hawryluk P. Kent .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Azoulay Salomon | Chief Medical Officer | Sell | 370 | $65.77 | $24.3K | 14,399 −2.5% of holding | |
| Azoulay Salomon 2 fills | Chief Medical Officer | Sell 10b5-1 | 70,003 | $38.36 | $2.7M | 14,769 −82.6% of holding | |
| Hawryluk P. Kent | President & CEO | Sell | 607 | $29.54 | $17.9K | 727,667 −0.1% of holding | |
| Azoulay Salomon | Chief Medical Officer | Sell | 231 | $29.54 | $6.8K | 14,769 −1.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.